Evidence map›Paper›PMID 42640121›Full record

ArticleJournal of managed care & specialty pharmacy2026

Comparative performance of large language models for appraising bias in real-world evidence studies.

Chijioke M Okeke, Regina Nechi, Javeria Khalid, Ibraheem M Karaye, J Douglas Thornton, Ismaeel Yunusa

Abstract readComparative Study
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chijioke M OkekeThe Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston.
Regina NechiDepartment of Outcomes and Translational Sciences, College of Pharmacy, The Ohio State University, Columbus.
Javeria KhalidDepartment of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston.
Ibraheem M KarayeDepartment of Population Health, Hofstra University, Hempstead, NY.
J Douglas ThorntonThe Prescription Drug Misuse Education and Research (PREMIER) Center, College of Pharmacy, University of Houston, Houston.
Ismaeel YunusaDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world evidence (RWE) is increasingly used to inform regulatory and payer policy decisions and health technology assessment, yet appraising the methodological credibility of RWE studies remains time-intensive and requires specialized expertise. The appraisal task could involve using an appraisal tool that provides a structured approach for evaluating bias in observational studies of comparative effectiveness and safety. Large language models (LLMs) may offer a scalable means to support this appraisal process, but their performance on structured bias assessment tasks has not been fully characterized.

objectiveTo compare the performance of LLMs from 6 major artificial intelligence (AI) technology providers against human expert assessments in appraising bias in published RWE studies using the Appraisal of Potential Bias in Real-World Evidence Studies framework.

methodsWe conducted a comparative diagnostic accuracy study evaluating 40 LLMs from OpenAI, Anthropic, Google, xAI, Meta, and DeepSeek. Ten published RWE studies representing diverse pharmacoepidemiological designs and data sources were appraised by each LLM using a structured chain-of-thought prompt with conditional rubric injection based on the Appraisal of Potential Bias in Real-World Evidence Studies framework. Two independent human reviewers with pharmacoepidemiology training evaluated each study, with a third adjudicator resolving disagreements to establish the reference standard. LLM performance was assessed using overall accuracy and macro-averaged precision, recall, and F1 scores. Assessment time was compared between models and benchmarked against human reviewers. Bootstrap method was used to construct 95% CI for performance measures.

resultsAcross 280 item-level assessments per model (10 studies × 28 items), overall accuracy ranged from 12.9% to 66.1%. The highest-performing model was Claude-Sonnet-4.6 (66.1%), followed by o3 (65.4%) and Gemini-3.1-pro-preview (65.0%). Macro-averaged F1 scores ranged from 30.9% to 66.9%; o3 achieved the highest F1 score (66.9%), followed by GROK-4 (65.5%) and Gemini-3.1-pro-preview (65.4%). Human reviewers required an average of 61.05 minutes per study; all LLMs completed assessments substantially faster, with average time per study ranging from 0.80 to 17.22 minutes relative to humans.

conclusionsLLMs hold considerable promise for automating methodological appraisal of RWE studies; however, their performance is variable and model dependent. Their greatest value may lie in enhancing efficiency and supporting human-led appraisal as decision-support tools rather than replacing expert review. Future research should assess performance across larger, more diverse RWE study collections and evaluate output reproducibility across repeated runs.

Indexed as

Large Language ModelsPharmacoepidemiologyTechnology Assessment, BiomedicalArtificial IntelligenceBiasHumans

Identifiers

PMID42640121
PMCPMC13505367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.